Expanded Access Opens Window For Dose Optimization Studies In Cancer
The period after completion of pivotal trials but ahead of FDA approval provides an opportunity for oncology drug sponsors to conduct badly needed dose comparison trials, a multi-stakeholder panel says at the annual Conference on Clinical Cancer Research.
You may also be interested in...
FDA advisory committee will also consider whether appropriate dose was selected for Phase III trial of the oral deacetylase inhibitor in patients with relapsed multiple myeloma.
Review of Novartis’ lung cancer therapy highlights the difficulties of getting traditional dosing work done in the compressed development program of a “breakthrough” drug – and shows just how flexible the agency will be in gathering information for the accelerated programs.
FDA reviewers and outside experts discussed at length concerns about cardiovascular and other adverse events in the single-arm PACE trial but believed ponatinib’s impressive efficacy in a difficult-to-treat leukemia population warranted bringing the drug to market. Sales of the tyrosine kinase inhibitor were halted less than 11 months later as safety and dosing concerns continued to pile up.